US 11,965,037 B2
Anti-HER3 humanized monoclonal antibody
Aidong Qu, Shanghai (CN); Hongyuan Liang, Shanghai (CN); Fanhong Xu, Shanghai (CN); Aoxiang Li, Shanghai (CN); Lina Wu, Shanghai (CN); Jingye Zhu, Shanghai (CN); Jianhua Qiu, Shanghai (CN); Jin Lu, Shanghai (CN); Lin Zhang, Shanghai (CN); Xin Zhao, Shanghai (CN); and Xiaofei Song, Shanghai (CN)
Assigned to SHANGHAI INSTITUTE OF BIOLOGICAL PRODUCTS CO., LTD., Shanghai (CN)
Appl. No. 17/260,442
Filed by SHANGHAI INSTITUTE OF BIOLOGICAL PRODUCTS CO., LTD., Shanghai (CN)
PCT Filed Jul. 17, 2019, PCT No. PCT/CN2019/096418
§ 371(c)(1), (2) Date Jan. 14, 2021,
PCT Pub. No. WO2020/015687, PCT Pub. Date Jan. 23, 2020.
Claims priority of application No. 201810784050.1 (CN), filed on Jul. 17, 2018.
Prior Publication US 2021/0277144 A1, Sep. 9, 2021
Int. Cl. C07K 16/32 (2006.01); A61K 47/68 (2017.01); A61P 35/00 (2006.01); C07K 14/71 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/32 (2013.01) [A61K 47/6851 (2017.08); A61P 35/00 (2018.01); C07K 14/71 (2013.01); A61K 2039/505 (2013.01)] 15 Claims
 
1. An anti-HER3 antibody, wherein the antibody comprises:
a light chain variable region comprising an amino acid sequence selected from the group consisting of: SEQ ID NO: 3 and SEQ ID NO: 7 and a heavy chain variable region comprising an amino acid sequence selected from the group consisting of: SEQ ID NO: 4 and SEQ ID NO: 8.